Biochemical and Toxicological Evaluation of Atorvastatin and Riboflavin in Diethylnitrosamine Induced Hepatocellular Carcinoma

Abstract

Background: Atorvastatin, a commonly prescribed drug for the management of hyperlipidemia, acts as competitive inhibitors of HMG-CoA reductase-a rate-limiting enzyme in cholesterol synthesis. On the other hand, riboflavin is also a well-studied micronutrient known for its anti-proliferative, antimetastatic and antioxidant properties. However, the synergistic or antagonistic effect of both drugs when administered together is not studied yet. Method: This study was an attempt to evaluate the toxicity/efficacy of atorvastatin (30 mg/kg) in combination with riboflavin in hepatocarcinogenic rats when challenged by a single diethylnitrosamine DENA (160 mg/kg; I.